

This promotional meeting is organised and fully funded by Advanced Accelerator Applications International S.A. (AAA), a Novartis company, and intended for healthcare professionals that treat patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

Prescribing information can be found at <https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera> and adverse events reporting information can be found at the end of this email.



UP FOR DEBATE WEBINAR SERIES 2022



MedTalks
AWARENESS. INSIGHT. ACTION.

LUTATHERA® ▼: STRATEGIES TO IMPROVE THE PATIENT JOURNEY AND REFERRAL PROCESS

Wednesday 22 June 2022
11:00–12:30 CEST and 18:00–19:30 CEST

Dear colleague,

We are delighted to invite you to an interactive webinar sponsored by Advanced Accelerator Applications International S.A., a Novartis company.

Join our expert faculty, Professor Philippe Ruszniewski, Professor Vineet Prakash, Professor Changhoon Yoo and Dr Marc Simó, as they explore clinical decision making at second line for patients with GEP-NETs and how to improve the patient journey to receiving LUTATHERA®, with many opportunities for Q&A.



PROF. PHILIPPE RUSZNIEWSKI

University of Paris VII,
Beaujon Hospital,
Paris, France



PROF. VINEET PRAKASH

University of Surrey,
Royal Surrey
County Hospital,
Guildford, UK



PROF. CHANGHOON YOO

University of Ulsan,
Asan Medical Center,
Seoul, South Korea



DR MARC SIMÓ

Hospital Universitari
Vall d'Hebron,
Barcelona, Spain

TIME (CEST)	SESSION	SPEAKER
11:00/18:00	Welcome and introduction	Prof. Philippe Ruszniewski
11:05/18:05	Introduction to LUTATHERA®	Dr Marc Simó
11:15/18:15	Panel discussion: What factors affect clinical decision making at second line for patients with GEP-NETs?	All faculty
11:30/18:30	Clinical cases using LUTATHERA®	Prof. Changhoon Yoo / Prof. Vineet Prakash
11:50/18:50	Panel discussion: How can we further improve the patient journey to receiving LUTATHERA®?	All faculty
12:05/19:05	Panel discussion: Practical and logistical considerations when referring patients for LUTATHERA®	All faculty
12:25/19:25	Close and thank you	Prof. Philippe Ruszniewski

REGISTER HERE



*This link will take you to a third-party website.
AAA is not responsible for the content or accuracy of this website.

ADVERSE EVENTS SHOULD BE REPORTED ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported to Advanced Accelerator Applications International S.A. at [Novartis PVI Report](#).

Confidentiality notice:

The information contained in this email is intended only for the individual or entity to whom it is addressed. It may contain privileged and confidential information and if you are not an intended recipient you must not copy, distribute, or take any action in reliance on it. If you have received this email in error, notify us immediately by email at dataprivacy.aaa@novartis.com. Please destroy and delete this message from your computer. If you wish to stop receiving emails from AAA, please reply "stop" to the following inbox: dataprivacy.aaa@novartis.com.

Further information is available from: Advanced Accelerator Applications International S.A., 4 rue de la Tour de L'île, 1204 Geneva, Switzerland.

AAA-Lu177-GL-0288 | May 2022